Drugs / betamethasone valerate
betamethasone valerate
also known as
betamethasone-17-valerate · Audavate · Audavate rd · Beta-val · Betaderm · Betameth val in coal tar · Betamethasone (as valerate) · Betamethasoni valeras · +20 more
Small molecule targets NR3C1 via activation
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | VALISONE | — | 1967-09-02 | fda.gov ↗ |
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02548052 | Oct 2015 → Feb 2016 | psoriasis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01646567 | Sep → Nov 2012 | psoriasis | TetraLogic Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04194814 | Nov 2020 → Sep 2021 | atopic eczema | Sheffield Teaching Hospitals NHS Foundation Trust | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05535738 | Nov 2022 → Jan 2027 expected | allergic contact dermatitis | Wei-Che Ko | Active not recruiting | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT01313221 | Apr 2011 → Dec 2012 | psoriasis | Amgen | Completed | Missed primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT05555797 | Oct 2022 → Sep 2023 | psoriasis | Assiut University | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07366268 | May 2026 → May 2027 expected | psoriasis | Assiut University | Not yet recruiting | No outcome recorded |
| Comparator or background therapy19 trials | ||||||
| Phase 1 | NCT06087796 Comparator | Oct 2023 → Sep 2024 | alopecia areata | Assiut University | Unknown | No outcome recorded |
| Phase 1 | NCT03669757 Comparator | Sep 2018 → Feb 2019 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT00358384 Comparator | Sep 2005 → Feb 2006 | psoriasis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT02518048 Comparator | Aug 2015 → Jan 2016 | connective tissue disorder | LEO Pharma | Completed | No outcome recorded |
| Phase 3 | NCT06643416 Comparator | Oct 2024 → Dec 2025 overdue | paronychia | Queen Mary Hospital, Hong Kong | Recruiting | No outcome recorded |
| Phase 3 | NCT06140186 Comparator | Apr → Dec 2023 | paronychia | Queen Mary Hospital, Hong Kong | Unknown | No outcome recorded |
| Phase 3 | NCT04476420 Comparator | Feb → Sep 2021 | oral submucous fibrosis | Ziauddin University | Completed | No outcome recorded |
| Phase 3 | NCT05969587 Background | Nov 2019 → Sep 2020 | hyperpigmentation of the skin | China Medical University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01011621 Comparator | Feb 2010 → Feb 2012 | atopic eczema, contact dermatitis, psoriasis, seborrheic dermatitis | Mantecorp Industria Quimica e Farmaceutica Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT00576238 Comparator | Jan 2004 → Feb 2008 | atopic eczema | ACO Hud Nordic AB | Completed | No outcome recorded |
| Phase 4 | NCT07508124 Comparator | Apr 2026 → Dec 2027 expected | urinary tract infection | Baylor College of Medicine | Recruiting | No outcome recorded |
| Phase 4 | NCT05285943 Comparator | Nov 2021 → Jan 2024 | radiodermatitis | Cairo University | Completed | No outcome recorded |
| Phase 4 | NCT02443311 Comparator | Sep 2010 → Jun 2012 | lichen planus, oral | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT00576550 Comparator | Oct 2007 → May 2008 | hand dermatosis | ACO Hud Nordic AB | Completed | No outcome recorded |
| — | NCT07696585 Comparator | Jun → Sep 2026 overdue | alopecia areata | Sohag University | Not yet recruiting | No outcome recorded |
| — | NCT07113756 Comparator | Sep → Dec 2025 overdue | psoriasis | Sohag University | Not yet recruiting | No outcome recorded |
| — | NCT06267066 Comparator | Mar → Aug 2024 | neurodermatitis | Cairo University | Unknown | No outcome recorded |
| — | NCT03983460 Comparator | Mar 2020 → Jun 2021 | atopic eczema | Association pour la Recherche Clinique et Immunologique | Unknown | No outcome recorded |
| — | NCT00608673 Comparator | Apr 2006 → Jul 2007 | discoid lupus erythematosus | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-08-02 | Xiromed LLC | Xiromed LLC Launches Betamethasone Valerate Foam, 0.12 xiromed.com ↗ |
| 2013-01-15 | Perrigo Company | Perrigo Announces Commercial Launch Of betamethasone valerate foam 0.12% perrigo.com ↗ |
| 2012-11-27 | Perrigo Company | Perrigo Announces FDA Final Approval Of Betamethasone Valerate Foam 0.12% perrigo.com ↗ |
| 2010-04-05 | Perrigo Company | Perrigo and Partner Cobrek Announce Settlement of Luxiq® Patent Litigation perrigo.com ↗ |
Evidence & citations 34 cited values
Every value below carries the sentence it was read from. 29 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | betamethasone valerate | “Application of betamethasone valerate 0.1% (Betneval 0.1% cream), a potent topical corticosteroid, and if not active, application of clobetasol propionate 0.05% (Dermoval 0.05%...” NCT03983460 ↗24“4% w/w hydroquinone cream (Melquine™) and 0.06% w/w betamethasone valerate cream (Rinderon®-V; equivalent to 0.05% betamethasone) were acquired from Sinphar Pharmaceutical Co.,...” NCT05969587 ↗ “Betamethasone (as valerate). Each 7.5 cm x 10 cm medicated plaster contains: 2.250 mg of betamethasone valerate (corresponding to 1.845 mg of betamethasone).(Betesil® )” NCT02518048 ↗ “* betamethasone valerate 0.1%” NCT01313221 ↗ |
| Known as | Audavate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1497 ↗ |
| Known as | Audavate rd | ChEMBL registry synonym — accepted as the source's own label CHEMBL1497 ↗ |
| Known as | Beta-val | ChEMBL registry synonym — accepted as the source's own label CHEMBL1497 ↗ |
| Known as | Betaderm | ChEMBL registry synonym — accepted as the source's own label CHEMBL1497 ↗ |
| Known as | Betameth val in coal tar | ChEMBL registry synonym — accepted as the source's own label CHEMBL1497 ↗ |
| Known as | Betamethasone (as valerate) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1497 ↗ |
| Known as | betamethasone-17-valerate | “The purpose of this study is to compare topical betamethasone-17-valerate and olive oil cream in preventing radiation-induced dermatitis (RID) in breast cancer patients and to...” PMID 40973558 ↗ Aug 20252“Betamethasone 17-valerate 2.25 mg (BV)-medicated plasters are recommended for treating psoriasis plaques localized in difficult-to-treat (DTT; elbow, knee, anterior face of the...” PMID 27995521 ↗ Apr 2017 |
| Known as | Betamethasoni valeras | ChEMBL registry synonym — accepted as the source's own label CHEMBL1497 ↗ |
| Known as | Betatrex | ChEMBL registry synonym — accepted as the source's own label CHEMBL1497 ↗ |
| Known as | Betesil | ChEMBL registry synonym — accepted as the source's own label CHEMBL1497 ↗ |
| Known as | Betneval 0.1% cream | “Application of betamethasone valerate 0.1% (Betneval 0.1% cream), a potent topical corticosteroid, and if not active, application of clobetasol propionate 0.05% (Dermoval 0.05%...” NCT03983460 ↗ |
| Known as | Betnovate | “Betamethasone 17-valerate 0.1% cream (Betnovate, GlaxoSmithKline, Cairo, Egypt)” NCT02443311 ↗ |
| Known as | Betnovate cream | “A total of 132 patients were randomized into three groups to receive either olive oil cream (G1), betamethasone-17-valerate (Betnovate® cream, GlaxoSmithKline) (G2), or...” PMID 40973558 ↗ Aug 2025 |
| Known as | Betnovate rd | ChEMBL registry synonym — accepted as the source's own label CHEMBL1497 ↗ |
| Known as | Betnovate-c | ChEMBL registry synonym — accepted as the source's own label CHEMBL1497 ↗ |
| Known as | Betnovate-n | ChEMBL registry synonym — accepted as the source's own label CHEMBL1497 ↗ |
| Known as | Bettamousse | ChEMBL registry synonym — accepted as the source's own label CHEMBL1497 ↗ |
| Known as | Bextasol | ChEMBL registry synonym — accepted as the source's own label CHEMBL1497 ↗ |
| Known as | Dermabet | ChEMBL registry synonym — accepted as the source's own label CHEMBL1497 ↗ |
| Known as | Fucibet | ChEMBL registry synonym — accepted as the source's own label CHEMBL1497 ↗ |
| Known as | Luxiq | ChEMBL registry synonym — accepted as the source's own label CHEMBL1497 ↗ |
| Known as | NSC-755912 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1497 ↗ |
| Known as | Rinderon-V | “4% w/w hydroquinone cream (Melquine™) and 0.06% w/w betamethasone valerate cream (Rinderon®-V; equivalent to 0.05% betamethasone) were acquired from Sinphar Pharmaceutical Co.,...” NCT05969587 ↗ |
| Known as | Stanoval | ChEMBL registry synonym — accepted as the source's own label CHEMBL1497 ↗ |
| Known as | Tokuderm | ChEMBL registry synonym — accepted as the source's own label CHEMBL1497 ↗ |
| Known as | Valisone | ChEMBL registry synonym — accepted as the source's own label CHEMBL1497 ↗ |
| Known as | Valnac | ChEMBL registry synonym — accepted as the source's own label CHEMBL1497 ↗ |
| Known as | Xemacort | ChEMBL registry synonym — accepted as the source's own label CHEMBL1497 ↗ |
| Action | Activate | “Glucocorticoid receptor agonist” CHEMBL1497 ↗ |
| Action | Inhibit | “BV suppresses the production of inflammatory cytokines and reduces keratinocyte hyperproliferation.” NCT05555797 ↗ |
| Modality | Small molecule | “0.1% betamethasone valerate ointment (class III steroid)” NCT03669757 ↗ |
| Route | Topical | “Betamethasone valerate ointment with 0.1 percent concentration will be given to subjects.” NCT00358384 ↗ |
| Target | NR3C1 | “Glucocorticoid receptor agonist” CHEMBL1497 ↗ |